INMED PHARMACEUTICALS INC
INMNASDAQTrading Snapshot
- Day Range
- $1.37 – $1.40
- 52-Week Range
- $0.58 – $2.50
- Volume
- $1.66B
- Avg Volume
- $2.14B
- Shares Outstanding
- 5.5M
- Next Earnings
- Dec 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.18B
- Last Q Revenue
- $2.06B
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +110504.2%
Why Investors Own INM
- ✓High-growth profile — revenue up +5.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 45% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INMED PHARMACEUTICALS INC
INM
StockOtter · stockotter.spaceAbout INMED PHARMACEUTICALS INC
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
InMed Pharmaceuticals Inc. (NASDAQ:INM) Shares Shorted: Short Interest Down 48.4% in September
InMed Pharmaceuticals Inc. (NASDAQ: INM - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 15,876 shares, a
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small mol
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small mole
Financial Survey: InMed Pharmaceuticals (NASDAQ:INM) & Reviva Pharmaceuticals (NASDAQ:RVPH)
InMed Pharmaceuticals (NASDAQ: INM - Get Free Report) and Reviva Pharmaceuticals (NASDAQ: RVPH - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companie
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline
Mentari Therapeutics, a privately held biotechnology enterprise dedicated to preventing migraines, has successfully secured an additional $200 million through a new private placement.
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 million private placement